Anthony Zietman
Papers
2
Total Citations
470
H-Index
2
About
Anthony Zietman is a leading figure in radiation oncology, whose research has fundamentally shaped the management of prostate cancer. His key contributions lie in risk stratification and evidence-based treatment, particularly for low-risk disease. Zietman’s most impactful work includes a landmark 2012 comparative analysis (with 459 citations) from the Prostate Cancer Results Study Group, which systematically evaluated prostate-specific antigen (PSA) free survival outcomes across treatment modalities for low, intermediate, and high-risk patients. This study provided critical, data-driven insights into treatment effectiveness, helping clinicians and patients navigate complex therapeutic decisions. Additionally, his provocative 2009 paper on “Evidence-Based Medicine, Conscience-Based Medicine, and the Management of Low-Risk Prostate Cancer” challenged the prevailing dogma of aggressive early intervention, arguing for more nuanced, patient-centered approaches. Through these contributions, Zietman has not only advanced the science of radiation therapy but also championed a more thoughtful, evidence-based paradigm in oncology, earning him widespread respect and a lasting influence on clinical practice.
Research Focus
Key Achievements
Top Papers
- 1
- 2